Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Rapid Micro Biosystems (Nasdaq: RPID) is set to release its first quarter 2023 financial results on May 5, 2023, before market opening. The release will be accompanied by a webcast conference call at 8:30 AM EST, which will be accessible for replay for one year. The company specializes in automation solutions that enhance the manufacturing processes for healthcare products, including vaccines and biologics. Their Growth Direct System modernizes microbial quality control testing for pharmaceutical manufacturers, aiming to improve efficiency and compliance. Headquartered in Lowell, Massachusetts, Rapid Micro also has global operations in Europe.
Rapid Micro Biosystems (Nasdaq: RPID) reported fourth quarter 2022 commercial revenue of $4.4 million, down from $5.2 million in Q4 2021. For full year 2022, total revenue was $17.1 million, a decline from $23.2 million in 2021. However, the recurring commercial revenue reached $11.0 million, a significant growth of 40%. The company forecasted 2023 revenue of at least $22.0 million, reflecting an approximate 30% increase. Notably, they maintained $138.4 million in cash with no debt. The net loss for Q4 2022 was $16.4 million, worsening from $14.6 million in Q4 2021.